ReviewMolecular biology reports2026
Beyond scarring: a next-generation vision for pulmonary fibrosis management.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial pulmonary fibrosis remains a progressive, fatal lung disease with a median survival of approximately 4-5 years in contemporary registry data and limited therapies that slow but do not halt or reverse fibrosis. A fundamental reconceptualization of IPF from a static scar to a dynamic, cellularly heterogeneous ecosystem is emerging, driven by recent technological breakthroughs.
methodsThis review synthesizes and critically evaluates peer-reviewed literature and clinical trial data from 2015 to 2025. We integrate findings from single-cell and spatial transcriptomics, artificial intelligence (AI)-enhanced imaging, and clinical studies on regenerative and targeted therapies to construct a new framework for IPF management. OUTCOMES: Single-cell atlases have revealed unprecedented pathological cellular states, including epithelial-mesenchymal hybrid cells and specialized fibroblast niches (HAS1hi, PLIN2
conclusionThe convergence of single-cell biology, computational medicine, and regenerative strategies establishes a new "Beyond Scarring" paradigm. This framework moves the therapeutic goal beyond deceleration of fibrosis toward active lung repair and functional restoration. Future IPF management will require interdisciplinary integration, biomarker-driven patient stratification, and a focus on aging-related mechanisms. This synthesis provides a roadmap for transforming IPF from an incurable terminal illness into a manageable condition, emphasizing quality of life and personalized care.
Indexed as
Identifiers
42240739What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.